Navigation Links
Multiple Sclerosis Patients to Benefit With AVONEX(R) Nurse Services Program

Biogen Idec announced the national launch of the new AVONEX(R) (Interferon beta-1a) Nurse Services program which is designed to help people //with multiple sclerosis (MS) as they begin and continue treatment with AVONEX, the most prescribed treatment for relapsing forms of MS worldwide.

"As a person living with MS and as a nurse I can attest first-hand that nurses play an important role in working closely with patients and their healthcare providers in both the treatment and care of MS," said Marie Stallbaum, RN, BSN, a nurse with the AVONEX Nurse Services Program. "Nurses in this program will be dedicated to helping MS patients live the fullest and most active lives possible."

The AVONEX Nurse Services program will have registered nurses covering the majority of the country who will provide a wide range of services that will help patients in a home setting. Services include:

?At-home injection training and follow-up visit(s)
?Assistance in managing injection anxiety)
?Management of disease expectations
?Tips for managing common side effects
?Valuable phone counseling
"The AVONEX Nurse Services program is the latest example of our efforts to provide the best care and support for patients," said Michael Panzara, MD, MPH, Vice President and Chief Medical Officer, Neurology Strategic Business Unit, Biogen Idec. "From our research efforts aimed at discovering new treatment options to the unparalleled support services we offer patients, Biogen Idec is committed to advancing the care of people living with MS."

AVONEX has been proven to slow the progression of physical disability, reduce the frequency of relapses, and is effective for patients who have their first clinical MS attack and have a brain MRI scan that suggests MS. AVONEX is also the only once-a-week therapy for MS.

The clinical benefits of AVONEX have been supported by a number of recent enhancements to the product's delivery. AVONEX can now be administered with a smaller needle, which can further advance patient comfort. The storage and transportation of AVONEX has been made even easier with the introduction of ambient storage for the AVONEX luer-lock prefilled syringe. A new AVOGRIP(TM) is available to aid patients in the administration of injections. These improvements are part of the company's efforts to improve patients' experience with AVONEX. In addition, AVONEX patients have shown significantly higher adherence rates than the other approved disease-modifying therapies (DMTs).(1)

AVONEX is the most prescribed treatment for relapsing forms of MS worldwide, with more than 130,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is marketed internationally in more than 90 countries.

AVONEX was the first treatment approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS; this use was approved in Europe in 2002 and in the U.S. in 2003. The most common side effects associated with AVONEX multiple sclerosis treatment are flu-like symptoms, including myalgia, fever, fatigue, headache, chills, nausea, vomiting, pain and asthenia.

AVONEX should be used with caution in patients with depression or other mood disorders and in patients with seizure disorders. AVONEX should not be used by pregnant women. Patients with cardiac disease should be closely monitored. Patients should also be monitored for signs of hepatic injury. Routine periodic blood chemistry and hematology tests are recommended during treatment with AVONEX. Rare cases of anaphylaxis have been reported

Source-IANS/N
'"/>




Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent ... is MD Now’s 28th facility overall and marks the urgent care center's eighth location ... mile North of The Falls shopping mall. The new clinic offers a wide array ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
(Date:5/23/2017)... 2017  Leaf Healthcare, recognized for developing one ... pressure ulcer prevention, will unveil its comprehensive mobility ... Care Nurses, National Teaching Institute and Critical Care ... Leaf Patient Monitoring System is the first mobility ... The system seamlessly tracks patient movement throughout the ...
Breaking Medicine Technology: